Results 131 to 140 of about 809,825 (355)

Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants

open access: yesMolecules, 2016
The human Epidermal Growth Factor (EGFR) plays an important role in signaling pathways, such as cell proliferation and migration. Mutations like G719S, L858R, T790M, G719S/T790M or T790M/L858R can alter its conformation, and, therefore, drug responses ...
María Jesús García-Godoy   +4 more
doaj   +1 more source

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. [PDF]

open access: yes, 2010
Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth.
Bigner, DD   +10 more
core  

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

open access: yesAdvanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang   +9 more
wiley   +1 more source

Antibody‐Programmable Bimetallic Nanozymes for Transcriptional Blockade Therapy in HER2/ER‐Positive Breast Cancer

open access: yesAdvanced Functional Materials, EarlyView.
Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao   +8 more
wiley   +1 more source

Research progress in targeted therapy for gastric cancer

open access: yesZhongguo linchuang yanjiu
Gastric cancer is a common malignant tumor worldwide, and its incidence rate and mortality have always been in the forefront. Most gastric cancer patients in China are diagnosed in the middle or late stages, with an unsatisfactory 5- year survival rate ...
WU Tengfei*, ZHAO Jinjin, LIN Jianxiu, TIAN Yun
doaj   +1 more source

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations [PDF]

open access: bronze, 2011
Tommaso De Pas   +10 more
openalex   +1 more source

Printing Nacre‐Mimetic MXene‐Based E‐Textile Devices for Sensing and Breathing‐Pattern Recognition Using Machine Learning

open access: yesAdvanced Functional Materials, EarlyView.
This study presents a Ti3C2Tx MXene/WPU nacre‐mimetic nanomaterial as a printable ink for direct‐write printing onto textiles‐based sensors. The resulting wearable device demonstrates high sensitivity, biocompatibility, and mechanical strength. Furthermore, NFC‐enabled humidity sensor produces time‐series data, which informs a machine learning ...
Lulu Xu   +6 more
wiley   +1 more source

Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates Epidermal Growth Factor Receptor in prostate cancer [PDF]

open access: diamond, 2016
Nathan Bucay   +10 more
openalex   +1 more source

Aptamer Functionalized Hydrogel Dressings for Post‐Surgery Tumor Recurrence Inhibition and Tissue Reconstruction

open access: yesAdvanced Functional Materials, EarlyView.
Post‐surgical tumor therapy struggles with recurrence and inefficient healing. Anti‐tumor DNA aptamer functionalized gelatin hydrogels, Apt‐GelMA, simultaneously address both issues by suppressing tumor regrowth via targeted tumor cell inhibition and enhancing wound healing through improved cell adhesion and migration. Their biocompatibility, stability,
Tianyue Li   +11 more
wiley   +1 more source

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. [PDF]

open access: yes, 2018
Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2.
Austin, David   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy